JP2021502379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502379A5 JP2021502379A5 JP2020525974A JP2020525974A JP2021502379A5 JP 2021502379 A5 JP2021502379 A5 JP 2021502379A5 JP 2020525974 A JP2020525974 A JP 2020525974A JP 2020525974 A JP2020525974 A JP 2020525974A JP 2021502379 A5 JP2021502379 A5 JP 2021502379A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- duraglutide
- dose
- once
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 13
- 230000002641 glycemic effect Effects 0.000 claims 12
- 239000004480 active ingredient Substances 0.000 claims 10
- 230000003442 weekly effect Effects 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 230000037221 weight management Effects 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000001509 sodium citrate Substances 0.000 claims 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 2
- 229940038773 trisodium citrate Drugs 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022014339A JP2022062153A (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2024021637A JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589244P | 2017-11-21 | 2017-11-21 | |
| US62/589,244 | 2017-11-21 | ||
| PCT/US2018/060716 WO2019103875A2 (en) | 2017-11-21 | 2018-11-13 | Methods of using and compositions containing dulaglutide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022014339A Division JP2022062153A (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502379A JP2021502379A (ja) | 2021-01-28 |
| JP2021502379A5 true JP2021502379A5 (enExample) | 2021-03-11 |
| JP7221956B2 JP7221956B2 (ja) | 2023-02-14 |
Family
ID=64572530
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525974A Active JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2022014339A Pending JP2022062153A (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2024021637A Pending JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022014339A Pending JP2022062153A (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2024021637A Pending JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11576950B2 (enExample) |
| EP (1) | EP3713593A2 (enExample) |
| JP (3) | JP7221956B2 (enExample) |
| KR (2) | KR102589234B1 (enExample) |
| CN (2) | CN111356472A (enExample) |
| AU (2) | AU2018372709B2 (enExample) |
| BR (1) | BR112020007817A2 (enExample) |
| CL (1) | CL2020001252A1 (enExample) |
| CR (1) | CR20200202A (enExample) |
| DO (1) | DOP2020000104A (enExample) |
| EA (1) | EA202090971A1 (enExample) |
| EC (1) | ECSP20026436A (enExample) |
| IL (1) | IL274563B2 (enExample) |
| JO (1) | JOP20200126A1 (enExample) |
| MA (1) | MA50798A (enExample) |
| MX (1) | MX2020005231A (enExample) |
| PE (1) | PE20200847A1 (enExample) |
| PH (1) | PH12020550795A1 (enExample) |
| SG (1) | SG11202003687RA (enExample) |
| UA (1) | UA127588C2 (enExample) |
| WO (1) | WO2019103875A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220143187A1 (en) * | 2019-03-15 | 2022-05-12 | Eli Lilly And Company | Preserved formulations |
| US20230088005A1 (en) * | 2020-01-30 | 2023-03-23 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| CN115605185A (zh) * | 2020-05-19 | 2023-01-13 | 豪夫迈·罗氏有限公司（Ch） | 螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途 |
| BR112023027321A2 (pt) | 2021-06-23 | 2024-03-12 | Lilly Co Eli | Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03005036A (es) | 2000-12-07 | 2003-09-05 | Lilly Co Eli | Proteinas de fusion glp-1. |
| ATE525395T1 (de) | 2003-06-12 | 2011-10-15 | Lilly Co Eli | Fusions proteine von glp-1-analoga |
| SI1831252T1 (sl) | 2004-12-22 | 2009-12-31 | Lilly Co Eli | Formulacije analogov glp-1 fuzijskih proteinov |
| WO2009009562A2 (en) | 2007-07-10 | 2009-01-15 | Eli Lilly And Company | Glp-1-fc fusion protein formulation |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| FI3630164T3 (fi) | 2017-06-01 | 2023-11-06 | Lilly Co Eli | Dulaglutidi kroonisen munuaissairauden hoitoon |
-
2018
- 2018-11-13 EA EA202090971A patent/EA202090971A1/ru unknown
- 2018-11-13 EP EP18812499.4A patent/EP3713593A2/en active Pending
- 2018-11-13 BR BR112020007817-4A patent/BR112020007817A2/pt unknown
- 2018-11-13 JO JOP/2020/0126A patent/JOP20200126A1/ar unknown
- 2018-11-13 AU AU2018372709A patent/AU2018372709B2/en active Active
- 2018-11-13 MX MX2020005231A patent/MX2020005231A/es unknown
- 2018-11-13 CR CR20200202A patent/CR20200202A/es unknown
- 2018-11-13 IL IL274563A patent/IL274563B2/en unknown
- 2018-11-13 UA UAA202002355A patent/UA127588C2/uk unknown
- 2018-11-13 CN CN201880075369.5A patent/CN111356472A/zh active Pending
- 2018-11-13 KR KR1020207014456A patent/KR102589234B1/ko active Active
- 2018-11-13 PH PH1/2020/550795A patent/PH12020550795A1/en unknown
- 2018-11-13 KR KR1020227035115A patent/KR20220146656A/ko not_active Ceased
- 2018-11-13 CN CN202510640885.XA patent/CN120478602A/zh active Pending
- 2018-11-13 WO PCT/US2018/060716 patent/WO2019103875A2/en not_active Ceased
- 2018-11-13 SG SG11202003687RA patent/SG11202003687RA/en unknown
- 2018-11-13 JP JP2020525974A patent/JP7221956B2/ja active Active
- 2018-11-13 US US16/763,269 patent/US11576950B2/en active Active
- 2018-11-13 MA MA050798A patent/MA50798A/fr unknown
- 2018-11-13 PE PE2020000547A patent/PE20200847A1/es unknown
-
2020
- 2020-05-12 CL CL2020001252A patent/CL2020001252A1/es unknown
- 2020-05-20 EC ECSENADI202026436A patent/ECSP20026436A/es unknown
- 2020-06-01 DO DO2020000104A patent/DOP2020000104A/es unknown
-
2022
- 2022-02-01 JP JP2022014339A patent/JP2022062153A/ja active Pending
- 2022-05-18 AU AU2022203372A patent/AU2022203372B2/en active Active
-
2023
- 2023-01-04 US US18/149,982 patent/US20240189394A1/en active Pending
-
2024
- 2024-02-16 JP JP2024021637A patent/JP2024056908A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11872266B2 (en) | Rapid-acting insulin compositions | |
| Bourgonje et al. | N-acetylcysteine and hydrogen sulfide in coronavirus disease 2019 | |
| JP2022062153A5 (enExample) | ||
| US12343342B2 (en) | Methods for treating soft tissue sarcoma | |
| JP2021502379A5 (enExample) | ||
| Ding et al. | Adiponectin protects rat myocardium against chronic intermittent hypoxia-induced injury via inhibition of endoplasmic reticulum stress | |
| Donald et al. | Para-aminosalicylic acid: the return of an old friend | |
| JP2018111728A5 (enExample) | ||
| JP2018138578A5 (enExample) | ||
| Vilay et al. | Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis | |
| Wenk et al. | The new world health organization recommendations on perioperative administration of oxygen to prevent surgical site infections: a dangerous reductionist approach? | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| JP2016539921A5 (enExample) | ||
| JP7374163B2 (ja) | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 | |
| RU2018140900A (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| JP2019524888A5 (enExample) | ||
| Bersanelli et al. | The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients | |
| CN110461329A (zh) | 治疗血癌的PPARγ激动剂 | |
| Lee et al. | Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV? | |
| US20090142298A1 (en) | Apolactoferrin Compositions and Methods for Their Use in the Treatment of Viral Hepatitis C | |
| Takahashi et al. | Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin | |
| Shashibhushan et al. | Paraquat: A fatal poison | |
| JP2020510028A5 (enExample) | ||
| JP2019507174A5 (enExample) | ||
| Aycicek et al. | Efficacy of deferasirox in children with β‐thalassemia: Single‐center 3 year experience |